Insider information: Faron Initiates Phase 2 Part of BEXMAB Study of Bexmarilimab in HMA-failed MDS
November 06, 2023 02:00 ET
|
Faron Pharmaceuticals Oy
MDS patients who have failed prior HMA therapy selected as first indication to advance into Phase 2 3 mg/kg and 6 mg/kg doses selected in accordance with FDA’s Project Optimus initiative guidancePhase...
Faron to Present Phase 1/2 Data From BEXMAB Study of Bexmarilimab in Combination with Standard of Care in Myeloid Malignancies at the 65th American Society of Hematology Annual Meeting
November 02, 2023 09:00 ET
|
Faron Pharmaceuticals Oy
TURKU, Finland and BOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via...
Inside Information: Announcement of the Results of Placing, the Issue Price and registration of Placing Shares with the Trade Register
October 27, 2023 02:05 ET
|
Faron Pharmaceuticals Oy
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED...
Inside information: Faron Announces Positive BEXMAB Study Update in Relapsed/Refractory AML and HMA-Refractory MDS Patients
October 11, 2023 07:00 ET
|
Faron Pharmaceuticals Oy
Bexmarilimab produces a 50% remission rate in doublet dose cohorts (11 out of 22 patients)Eight of the 11 patients are Complete Responders (CR) or CR with incomplete blood recovery (CRi)Highest...
Faron to Host Webcast to Discuss New Data From Phase I/II BEXMAB Study of Bexmarilimab and Provide Update on the Development Outlook for Next 6-9 Months
October 03, 2023 02:00 ET
|
Faron Pharmaceuticals Oy
TURKU, Finland and BOSTON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pioneering macrophage re-programming...
Faron Pharmaceuticals Announces Board Changes
September 22, 2023 11:00 ET
|
Faron Pharmaceuticals Oy
TURKU, Finland and BOSTON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via...
Faron Pharmaceuticals Ltd Results of the Extraordinary General Meeting
September 22, 2023 06:33 ET
|
Faron Pharmaceuticals Oy
TURKU, Finland and BOSTON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via...
Faron Appoints Dr. Birge Berns, MD as Interim Chief Medical Officer
September 21, 2023 02:00 ET
|
Faron Pharmaceuticals Oy
• Dr. Marie-Louise Fjällskog, outgoing CMO, is proposed to continue key role in bexmarilimab’s development as a Board member Company announcement, September 21, 2023 TURKU, Finland and BOSTON,...
Faron Pharmaceuticals Ltd. to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023 02:00 ET
|
Faron Pharmaceuticals Oy
TURKU, Finland and BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers...
Faron Reports Half-Year Financial Results, January 1 – June 30, 2023
August 29, 2023 00:01 ET
|
Faron Pharmaceuticals Oy
Summary Highlights (including post-period events) The US Food and Drug Administration (FDA) granted bexmarilimab Orphan Drug Designation (ODD) for the treatment of acute myeloid leukemia (AML).The...